

PTO/SB/08 (2/92)  
Sheet 1 of 1

<b>Form PTO-1449</b>  <b>INFORMATION DISCLOSURE STATEMENT</b>		Attorney's Docket No. <b>39750-0065DV1</b>		Application Serial No. <b>10/621,855</b>			
		Applicant(s) <b>Frederic J. de SAUVAGE, et al.</b>					
(use several sheets if necessary)		Filing Date: <b>July 16, 2003</b>		Group Art Unit: <b>1653 / 1649</b>			
		<b>U.S. PATENT DOCUMENTS</b>					
Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date (if appropriate)
<b>FOREIGN PATENT DOCUMENTS</b>							
Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Translation YES NO
<b>OTHER DOCUMENTS</b> (including author, title, date, pertinent pages, etc.)							
Examiner Initials	Ref. No.	Title					
REV ↓	1	Andres et al., <i>Development</i> 128(10):3685-3695 (2001) Multiple effects of artemin on sympathetic neurone generation, survival and growth.					
	2	Baloh et al., <i>Neuron</i> 21: 1291-1302 (1998) Artemin, a novel member of the GDNF ligand family, supports peripheral and central neurons and signals through the GFRalpha3-RET receptor complex.					
	3	Esteve, "Monoclonal Antibodies, Small Molecules, and Vaccines in the Treatment of Breast Cancer," <i>The Oncologist</i> 9(Suppl 3):4-9 (2004), page 6, column 1, lines 8-16).					
	4	Negro et al., <i>Recent Prog Horm Res.</i> 59:1-12 (2004) Essential roles of Her2/erbB2 in cardiac development and function.					
	5	Rosická et al., <i>Physiological Research</i> 51:435-441 (2002) Ghrelin - a New Endogenous Growth Hormone Secretagogue.					
	6	Smith et al., <i>Best Pract Res Clin endocrinol Metab.</i> 18(3):333-347 (2004) Growth hormone secretagogues: prospects and potential pitfalls.					
	7	Thilenius et al., <i>Eur. J. Immunol.</i> 27(5):1108-1114 (1997) Agonist antibody and Fas ligand mediate different sensitivity to death in the signaling pathways of Fas and cytoplasmic mutants.					
EXAMINER: <i>P. J. Ryan</i>		DATE CONSIDERED: <i>3/21/06</i>					
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.							
*If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identical in the statement and relied upon for an earlier filing date under 35 U.S.C. §120. 37 C.F.R. §1.98 (d).							

FORM PTO-1449

U.S. Dept. of Commerce  
Patent and Trademark OfficeAtty. Docket No.  
39766-0065 DV1Serial No. 10/621855  
To be Assigned

## LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant  
Frederic J. de SAUVAGE, et al.Filing Date 7/16/03  
Herewith Group 1649  
To be Assigned

## U.S. PATENT DOCUMENTS

Examiner Initials	Ref No.	Document Number	Date	Name	Class	Subclass	Filing Date
PCV	*1	5,709,858	20.01.98	Godowski et al.	424	143.1	

## FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref No.	Document Number	Date	Country	Class	Subclass	Translation Yes	No
PCV	*2	307,247	15.03.89	EPO				
	*3	846,764	10.06.98	EPO				
	*4	WO 93/06116	01.04.93	PCT-WIPO				
	*5	WO 97/33912	18.09.97	PCT-WIPO				
	*6	WO 97/44356	27.11.97	PCT-WIPO				
	*7	WO 98/53069	26.11.98	PCT-WIPO				
	*8	WO 98/54213	03.12.98	PCT-WIPO				

## OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

PCV	*9	Arenas et al., "GDNF Prevents Degeneration and Promotes the Phenotype of Brain Noradrenergic Neurons in Vivo" <u>Neuron</u> 15:1465-1473 (1995).					
	*10	Baloh et al., "Artemin, a novel member of the GDNF ligand family, supports peripheral and central neurons and signals through the GFRα3-RET receptor complex" <u>Neuron</u> 21(6):1291-1302 (Dec 1998).					
	*11	Beck et al., "Mesencephalic dopaminergic neurons protected by GDNF from axotomy-induced degeneration in the adult brain" <u>Nature</u> 373:339-341 (1995).					
	*12	Berkemeier et al., "Neurotrophin-5: A Novel Neurotrophic Factor That Activates trk and trkB" <u>Neuron</u> 7:857-866 (November 1991).					
	*13	Bolivar et al., "Construction and Characterization of New Cloning Vehicles. II. A Multipurpose Cloning System" <u>Gene</u> 2:95-113 (1977).					
	*14	Buj-Bello et al., "GDNF Is an Age-Specific Survival Factor for Sensory and Autonomic Neurons" <u>Neuron</u> 15:821-828 (1995).					
	*15	Cash et al., "Parkinson's disease and dementia: Norepinephrine and dopamine in locus ceruleus" <u>Neurology</u> 37:42-46 (1987).					
	*16	Chan-Palay et al., "Alterations in Catecholamine Neurons of the Locus Coeruleus in Senile Dementia of the Alzheimer Type and in Parkinson's Disease With and Without Dementia and Depression" <u>The Journal of Comparative Neurology</u> 287:373-392 (1989).					
	*17	Durbec et al., "GDNF signalling through the Ret receptor tyrosine kinase" <u>Nature</u> 381:789-793 (1996).					
	*18	Hefti, F., "Nerve Growth Factor Promotes Survival of Septal Cholinergic Neurons After Fimbrial Transections" <u>J. of Neuroscience</u> 6(8):2155-2162 (August 1986).					
	*19	Henderson et al., "GDNF: A Potent Survival Factor for Motoneurons Present in Peripheral Nerve and Muscle" <u>Science</u> 266:1062-1064 (1994).					
	*20	Heumann, R., "Regulation of the Synthesis of Nerve Growth Factor" <u>J. Exp. Biol.</u> 132:133-150 (1987).					
	*21	Hirano, A., "Cytopathology of Amyotrophic Lateral Sclerosis" <u>Advances in Neurology: Amyotrophic Lateral Sclerosis and Other Motor Neuron Diseases</u> , Lewis P. Rowland, Raven Press, Ltd., Chapter 8, Vol. 56:91-101 (1991).					

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

\*If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identical in the statement and relied upon for an earlier filing date under 35 U.S.C. §120. 37 C.F.R. §1.98 (d).

M PTO-1449

U.S. Dept. of Commerce  
Patent and Trademark OfficeAtty Docket No.  
39766-0065 DV1Serial No. 10/621855  
~~To be Assigned~~

## LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant  
Frederic J. de SAUVAGE, et al.Filing Date 7/16/03  
~~Herewith~~Group 1649  
~~To be Assigned~~

Examiner Initials	Ref. No.	OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)
PJ	*22	Hirsch et al., "Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease" <u>Nature</u> 334:345-348 (1988),
	*23	Holmes et al., "Structure and Functional Expression of a Human Interleukin-8 Receptor" <u>Science</u> 253(5025):1278-1280 (Sep 13, 1991),
	*24	Hornykiewicz, O., "Neurochemical Pathology and the Etiology of Parkinson's Disease: Basic Facts and Hypothetical Possibilities" <u>Mr. Sinai J. Med.</u> 55:11-20 (1988),
	*25	Jing et al., "GDNF-Induced Activation of the Ret Protein Tyrosine Kinase Is Mediated by GDNFR- $\alpha$ , a Novel Receptor for GDNF" <u>Cell</u> 85:1113-1124 (1996),
	*26	Jing et al., "GFR $\alpha$ -2 and GFR $\alpha$ -3 Are Two New Receptors for Ligands of the GDNF Family" <u>Journal of Biological Chemistry</u> 272(52):33111-33117 (Dec 26, 1997),
	*27	Kaisho et al., "Cloning and expression of a cDNA encoding a novel human neurotrophic factor" <u>FEBS Letters</u> 266(1,2):187-191 (June 1990),
	*28	Kearns et al., "GDNF protects nigral dopamine neurons against 6-hydroxydopamine in vivo" <u>Brain Research</u> 672:104-111 (1995),
	29	Kotzbauer et al., "Neurturin, a relative of glial-cell-line-derived neurotrophic factor" <u>Nature</u> 384:467-470 (1996),
	*30	Leibrock et al., "Molecular Cloning and Expression of Brain-derived Neurotrophic Factor" <u>Nature</u> 341:149-152 (September 14, 1989),
	*31	Lin et al., "GDNF: A Glial Cell Line-Derived Neurotrophic Factor for Midbrain Dopaminergic Neurons" <u>Science</u> 260:1130-1132 (1993),
	*32	Maisonpierre et al., "Neurotrophin-3: A Neurotrophic Factor Related to NGF and BDNF" <u>Science</u> 247:1446-1451 (March 23, 1990),
	*33	Marcyniuk et al., "The Topography of Cell Loss from Locus Coeruleus in Alzheimer's Disease" <u>J. Neurol. Sci.</u> 76:335-345 (1986),
	*34	Melton et al., "Efficient in vitro synthesis of biologically active RNA and RNA hybridization probes from plasmids containing a bacteriophage SP6 promoter" <u>Nucleic Acids Research</u> 12(18):7035-7056 (Sep 25, 1984),
	*35	Moore et al., "Renal and neuronal abnormalities in mice lacking GDNF" <u>Nature</u> 382:76-79 (1996),
	*36	Oppenheim et al., "Developing motor neurons rescued from programmed and axotomy-induced cell death by GDNF" <u>Nature</u> 373:344-346 (1995),
	*37	Phillips et al., "Widespread expression of BDNF but not NT3 by target areas of basal forebrain cholinergic neurons" <u>Science</u> 250(4978):290-294 (Oct. 12, 1990),
	*38	Pichel et al., "Defects in enteric innervation and kidney development in mice lacking GDNF" <u>Nature</u> 382:73-76 (1996),
	*39	Rosenthal et al., "Primary Structure and Biological Activity of a Novel Human Neurotrophic Factor" <u>Neuron</u> 4:767-773 (May 1990),
	*40	Ruppert et al., "Cloning and Expression of Human TAF <sub>II</sub> 250: a TBP-associated Factor Implicated in Cell-cycle Regulation" <u>Nature</u> 362:175-179 (1993),
	*41	Sanchez et al., "Renal agenesis and the absence of enteric neurons in mice lacking GDNF" <u>Nature</u> 382:70-73 (1996),

EXAMINER: PJ

DATE CONSIDERED: 3/27/06

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

\*If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identical in the statement and relied upon for an earlier filing date under 35 U.S.C. §120. 37 C.F.R. §1.98 (d).

Atty Docket No. 39766-0065 DV1

Serial No. 10/621853  
~~To be Assigned~~

Applicant  
**Frederic J. de SAUVAGE, et al.**

(Use several sheets if necessary)

Filing Date 7/16/03  
Hereswith

Group 1649  
~~To be Assigned~~

[illegible]

**EXAMINER:**

**DATE CONSIDERED:**

3/27/06

**EXAMINER:** Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

\*If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identical in the statement and relied upon for an earlier filing date under 35 U.S.C. §120. 37 C.F.R. §1.98 (d).

## INFORMATION DISCLOSURE STATEMENT

## U.S. PATENT DOCUMENTS

**Examiner  
Initials**

# FOREIGN PATENT DOCUMENTS

**Examiner  
Initials**

## OTHER DOCUMENTS

(Including author, title, date, pertinent pages, etc.)

**Examiner  
Initials** \_\_\_\_\_

**EXAMINER:**

**DATE CONSIDERED:** 3/27/06

**EXAMINER:** Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

\*If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identical in the statement and relied upon for an earlier filing date under 35 U.S.C. §120. 37 C.F.R. §1.98 (d).

Form PTO-1449		Attorney's Docket No. <b>39750-0065DV1</b>		Application Serial No. <b>10/621,855</b>	
<b>INFORMATION DISCLOSURE STATEMENT</b>		Applicant(s) <b>Frederic J. de SAUVAGE, et al.</b>			
<i>(use several sheets if necessary)</i>		Filing Date: <b>July 16, 2003</b>		Group Art Unit: <b>1653- 1649</b>	
<b>U.S. PATENT DOCUMENTS</b>					
Examiner Initials	Ref. No.	Date	Document No.	Name	Class s
<b>FOREIGN PATENT DOCUMENTS</b>					
Examiner Initials	Ref. No.	Date	Document No.	Name	Class s
<b>OTHER DOCUMENTS</b> <i>(including author, title, date, pertinent pages, etc.)</i>					
Examiner Initials	Ref. No.	Title			
	1	Andres et al., <i>Development</i> 128(10):3685-3695 (2001) Multiple effects of artemin on sympathetic neurone generation, survival and growth			
	2	Balon et al., <i>Neuron</i> 21: 1291-1302 (1998) Artemin, a novel member of the GDNF ligand family, supports peripheral and central neurons and signals through the GFRalpha3-RET receptor complex			
	3	Esteve, "Monoclonal Antibodies, Small Molecules, and Vaccines in the Treatment of Breast Cancer," <i>The Oncologist</i> 9(Suppl 3):4-9 (2004), page 6, column 1, lines 8-16).			
	4	Negro et al., <i>Recent Prog Horm Res.</i> 59:1-12 (2004) Essential roles of Her2/erbB2 in cardiac development and function			
	5	Rosická et al., <i>Physiological Research</i> 51:435-441 (2002) Ghrelin - a New Endogenous Growth Hormone Secretagogue			
	6	Smith et al., <i>Best Pract Res Clin endocrinol Metab.</i> 18(3):333-347 (2004) Growth hormone secretagogues: prospects and potential pitfalls			
	7	Thilenius et al., <i>Eur. J. Immunol.</i> 27(5):1108-1114 (1997) Agonist antibody and Fas ligand mediate different sensitivity to death in the signaling pathways of Fas and cytoplasmic mutants			
EXAMINER:			DATE CONSIDERED:		
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.					
*If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identical in the statement and relied upon for an earlier filing date under 35 U.S.C. §120. 37 C.F.R. §1.98 (d).					

*duplicate citations*